Bavarian Nordic sells discount shares to help fund Covid-19 vaccine
Bavarian Nordic has completed a new round of selling equity and has raised USD 175.8m in gross proceeds, which will in part help finance the firm's Covid-19 vaccine and ease the way to new acquisitions.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Bavarian Nordic has sold shares worth DKK 1.1bn (USD 175.8m) at DKK 223 per share, which will partly go towards financing the company's further development of the Covid-19 vaccine which the firm has in-licensed from Adaptvac.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
